曼氏血吸虫:针对次黄嘌呤 - 鸟嘌呤磷酸核糖转移酶基因的基于RNA干扰的治疗评估
Schistosoma mansoni: evaluation of an RNAi-based treatment targeting HGPRTase gene.
作者信息
Pereira T C, Pascoal V D B, Marchesini R B, Maia I G, Magalhães L A, Zanotti-Magalhães E M, Lopes-Cendes I
机构信息
Departamento de Genética Médica, Universidade Estadual de Campinas, Cidade Universitária Zeferino Vaz, FCM, Unicamp-Campinas, São Paulo, Brazil 13084-971.
出版信息
Exp Parasitol. 2008 Apr;118(4):619-23. doi: 10.1016/j.exppara.2007.11.017. Epub 2008 Jan 30.
Hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) is an essential gene of the parasite Schistosoma mansoni and it is well conserved in its hosts (mouse and human) at the protein but not at the RNA level. This feature prompted us to assess RNA interference (RNAi) to combat schistosomiasis. Small interfering RNAs (siRNAs) were produced against HGPRTase, injected in infected mice and the number of worms was counted six days after injection. The total number of parasites was reduced by approximately 27% after treatment. RT-PCR analyzes showed a significant reduction in parasite target mRNA but not in host's homologue. The use of low doses of molecules did not oversaturate si- or miRNA pathways as mice survival rates were not affected by siRNAs. This is the first successful in vivo demonstration of a RNAi-based treatment against schistosomiasis. We believe that improvements in molecule delivery and an increase on siRNA dose could rapidly eliminate parasite.
次黄嘌呤 - 鸟嘌呤磷酸核糖转移酶(HGPRTase)是曼氏血吸虫的一个必需基因,它在其宿主(小鼠和人类)中蛋白质水平高度保守,但在RNA水平并非如此。这一特性促使我们评估RNA干扰(RNAi)用于对抗血吸虫病的效果。针对HGPRTase产生了小干扰RNA(siRNA),将其注射到受感染小鼠体内,并在注射六天后对虫体数量进行计数。治疗后寄生虫总数减少了约27%。逆转录 - 聚合酶链反应(RT-PCR)分析表明,寄生虫靶标mRNA显著减少,但宿主同源物未减少。低剂量分子的使用并未使siRNA或微小RNA(miRNA)途径过度饱和,因为小鼠存活率不受siRNA影响。这是首次成功在体内证明基于RNAi的血吸虫病治疗方法。我们相信,分子递送的改进和siRNA剂量的增加能够迅速消除寄生虫。